Literature DB >> 19116708

Relevance of short-term variation of B-type natriuretic peptide in patients with clinically stable heart failure.

Micha Tobias Maeder1, Dietrich Hack, Hans Rickli, Hans Peter Brunner-La Rocca, Walter Riesen, Peter Ammann.   

Abstract

BACKGROUND: In patients with clinically stable chronic heart failure, circulating B-type natriuretic peptide (BNP) levels may exhibit considerable variation over a period of a few days. The aim of this study was to evaluate the clinical impact of this phenomenon.
METHODS: In 23 patients with clinically stable mild-to-moderate systolic heart failure [median (interquartile range) 72 (64-77) years, left ventricular ejection fraction 30 (27-40)%] and a history of previous hospitalization for heart failure, BNP was measured at two time points [T1 and T2, interval 5 (3-7) days] for calculation of the absolute change in BNP concentrations between T1 and T2 (DeltaBNP; irrespective of whether there was a decrease or increase). Follow-up for rehospitalization was 436 (407-458) days.
RESULTS: In the group overall, DeltaBNP was 26 (9-116) pg/ml [19 (10-28)% of the value at T1]. During follow-up, 8/23 (35%) patients were rehospitalized. BNP concentrations at T1 [340 (187-533) vs. 210 (108-606) pg/ml; P = 0.33] and T2 [328 (125-491) vs. 259 (89-536) pg/ml; P = 0.51] were similar in patients who were rehospitalized and those who were not; however, DeltaBNP was higher in patients requiring rehospitalization [98 (36-186) vs. 19 (6-93) pg/ml; P = 0.04]. Patients with DeltaBNP <26 pg/ml had a longer rehospitalization-free survival than those with DeltaBNP > or = 26 pg/ml (log rank P = 0.02). Sensitivity and specificity of DeltaBNP > or = 26 pg/ml for the prediction of rehospitalization were 88% and 67% respectively.
CONCLUSIONS: In this small study among patients with clinically stable heart failure, higher DeltaBNP over a period of a few days was associated with a higher likelihood of rehospitalization during follow-up.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19116708     DOI: 10.1007/s00508-008-1099-x

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  28 in total

1.  Clinical relevance of biological variation of B-type natriuretic peptide.

Authors:  Aldo Clerico; Gian Carlo Zucchelli; Alessandro Pilo; Michele Emdin
Journal:  Clin Chem       Date:  2005-05       Impact factor: 8.327

2.  B-type natriuretic peptide in patients with sepsis and preserved left ventricular ejection fraction.

Authors:  Micha Maeder; Peter Ammann; Wolfgang Kiowski; Hans Rickli
Journal:  Eur J Heart Fail       Date:  2005-10-03       Impact factor: 15.534

3.  Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study.

Authors:  Sandeep R Das; Mark H Drazner; Daniel L Dries; Gloria L Vega; Harold G Stanek; Shuaib M Abdullah; Russell M Canham; Anne K Chung; David Leonard; Frank H Wians; James A de Lemos
Journal:  Circulation       Date:  2005-10-04       Impact factor: 29.690

4.  Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy.

Authors:  D R Murdoch; T A McDonagh; J Byrne; L Blue; R Farmer; J J Morton; H J Dargie
Journal:  Am Heart J       Date:  1999-12       Impact factor: 4.749

5.  B-type natriuretic peptide kinetics and cardiopulmonary exercise testing in heart failure.

Authors:  Micha Maeder; Thomas Wolber; Hans Rickli; Jonathan Myers; Dietrich Hack; Walter Riesen; Daniel Weilenmann; Peter Ammann
Journal:  Int J Cardiol       Date:  2006-12-19       Impact factor: 4.164

Review 6.  The biologic variability of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients.

Authors:  Rory O'Hanlon; Paula O'Shea; Mark Ledwidge; Christina O'Loughlin; Sophie Lange; Carmel Conlon; Dermot Phelan; Sean Cunningham; Ken McDonald
Journal:  J Card Fail       Date:  2007-02       Impact factor: 5.712

7.  Relationship between B-type natriuretic peptides and pulmonary capillary wedge pressure in the intensive care unit.

Authors:  Paul R Forfia; Stanley P Watkins; J Eduardo Rame; Kerry J Stewart; Edward P Shapiro
Journal:  J Am Coll Cardiol       Date:  2005-05-17       Impact factor: 24.094

Review 8.  Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results.

Authors:  Alan H B Wu
Journal:  Am Heart J       Date:  2006-11       Impact factor: 4.749

9.  B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure.

Authors:  Yoshitaka Iwanaga; Isao Nishi; Shinichi Furuichi; Teruo Noguchi; Kazuhiro Sase; Yasuki Kihara; Yoichi Goto; Hiroshi Nonogi
Journal:  J Am Coll Cardiol       Date:  2006-01-26       Impact factor: 24.094

10.  B-type natriuretic peptide and peak exercise oxygen consumption provide independent information for risk stratification in patients with stable congestive heart failure.

Authors:  Pascal de Groote; Joël Dagorn; Benoit Soudan; Nicolas Lamblin; Eugene McFadden; Christophe Bauters
Journal:  J Am Coll Cardiol       Date:  2004-05-05       Impact factor: 24.094

View more
  3 in total

1.  Atrial fibrillation is an independent determinant of increased NT-proBNP levels in outpatients with signs and symptoms of heart failure.

Authors:  Borut Jug; Miran Sebestjen; Miso Sabovic; Maja Pohar; Irena Keber
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

2.  Profiling B-type natriuretic peptide in a stable heart failure population: a valuable adjunct to care.

Authors:  A Jan; N F Murphy; C O'Loughlin; M Ledwidge; K McDonald
Journal:  Ir J Med Sci       Date:  2011-03-03       Impact factor: 1.568

3.  Serum levels of N-terminal pro-B-type natriuretic peptide are associated with allograft function in recipients of renal transplants.

Authors:  Gerd Bodlaj; Rainer Hubmann; Karim Saleh; Georg Biesenbach; Erich Pohanka; Tatjana Stojakovic; Jörg Berg
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.